Market Cap
$1.5B
ANAB
ANAPTYSBIO, INC
$48.61 ▼ -0.04%
Prev close $48.63Market cap$1.5B
ConsensusStrong Buy
12-mo target$87.25 (+79.5%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)23 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ANAB right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$998.6M
Inst. Activity
23 buys / 10 sells
Social Sentiment
67° Warm
SEC Reports
20
Press Releases
3
Price chart 30d -12.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Dec 12, 2026 fda_pdufa
PDUFA: ANAB — imsidolimab in generalized pustular psoriasis (GPP) — 2026-12-12
FDA target action date 2026-12-12 for ANAB (ANAPTYSBIO, INC). Drug: imsidolimab. Indication: general
Sep 15, 2026 Insider
Aug 12, 2026 SEC Orwin John A acquired via exercise 1,300 shares
Director
Seven institutional investors accumulated $73.2M in net new ANAB positions during Q2 2026, led by State Street (+$31.8M)
INST-CLUSTER — Impact 5/10
CEO Dennis Mulroy filed a Form 144 on June 26, 2026, indicating intent to sell 10,000 shares of AnaptysBio common stock,
144 — Impact 6/10
AnaptysBio filed definitive additional proxy soliciting materials (DEFA14A) for its August 11, 2026 Annual Meeting. The
DEFA14A — Impact 2/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
1,286,194 shares ($86.8M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
807,316 shares ($54.5M)
Jun 15, 2026 Insider
Orwin John A acquired via exercise 6,030 shares
Director
Analyst ratings buy % +11.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Sep 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 23, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Aug 25, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 13, 2026 | UBS | MAINTAIN | Buy | 55% |
| May 13, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| May 4, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% |
Price targets
Where 8 covering analysts think ANAB trades over the next 12 months.
$87.25 +79.5% upside Strong Buy
Current$48.61 Low$60.00 Median$79.50 High$140.00 8 analysts
$60.00$140.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +7.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 2 bullish, 13 bearish, 0 mixed, 5 neutral · avg impact 4.7/10.Plus 3 press releases.
BULLISHINST-CLUSTER5/10
Seven institutional investors accumulated $73.2M in net new ANAB positions during Q2 2026, led by St
Aug 12, 2026
BEARISH1446/10
CEO Dennis Mulroy filed a Form 144 on June 26, 2026, indicating intent to sell 10,000 shares of Anap
Jul 3, 2026
NEUTRALDEFA14A2/10
AnaptysBio filed definitive additional proxy soliciting materials (DEFA14A) for its August 11, 2026
Jul 3, 2026
BEARISH1446/10
Officer Dennis Mulroy filed a Form 144 to sell 9,476 shares (~$601K) of AnaptysBio, continuing a hea
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Dec 12, 2026
fda_pdufa
PDUFA: ANAB — imsidolimab in generalized pustular psoriasis (GPP) — 2026-12-12
FDA target action date 2026-12-12 for ANAB (ANAPTYSBIO, INC). Drug: imsidolimab. Indication: generalized pustular psoriasis (GPP). FDA accepted the BL
Sep 21, 2026
earnings
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli
Sep 11, 2026
earnings_calendar
ANAB Q2 2026 Earnings After Market Close — 2026-09-11
Aug 27, 2026
earnings_calendar
ANAB Q2 2026 Earnings After Market Close — 2026-08-27
Aug 10, 2026
earnings_calendar
ANAB Q2 2026 Earnings After Market Close — 2026-08-10
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.80 | $0.30–$1.29 | 53.1% | +107.2% | 0↑ 4↓ | $0.0B | 2 |
| Next Q | $1.54 | $1.08–$2.01 | -2.2% | +111.6% | 1↑ 2↓ | $0.1B | 2 |
| Current FY | $4.35 | $2.49–$7.06 | 1045.7% | +1031.0% | 0↑ 4↓ | $0.1B | 3 |
| Next FY | $5.07 | $2.69–$8.77 | 16.5% | +16.4% | 2↑ 2↓ | $0.2B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.796 | — |
| 7d ago | $0.796 | — |
| 30d ago | $0.384 | +0.412 |
| 60d ago | $0.384 | +0.412 |
| 90d ago | $0.384 | +0.412 |
Institutional ownership
Which big funds own ANAB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $998.6M total value (14,792,088 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 23 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 1,844,049 | $124.5M | 12.5% | — |
| STATE STREET CORP | 1,286,194 | $86.8M | 8.7% | ADD +29.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 906,233 | $61.2M | 6.1% | — |
| MILLENNIUM MANAGEMENT LLC | 807,316 | $54.5M | 5.5% | ADD +69.8% |
| Woodline Partners LP | 717,014 | $48.4M | 4.8% | DOUBLED +108.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 637,873 | $43.1M | 4.3% | — |
| GOLDMAN SACHS GROUP INC | 584,070 | $39.4M | 3.9% | ADD +75.5% |
| D. E. Shaw & Co., Inc. | 539,666 | $36.4M | 3.6% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 527,858 | $35.6M | 3.6% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 488,651 | $33.0M | 3.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 992,445 | 1,286,194 | +29.6% | $86.8M |
| MILLENNIUM MANAGEMENT LLC | ADD | 475,572 | 807,316 | +69.8% | $54.5M |
| Woodline Partners LP | DOUBLED | 344,256 | 717,014 | +108.3% | $48.4M |
| GOLDMAN SACHS GROUP INC | ADD | 332,743 | 584,070 | +75.5% | $39.4M |
| Nuveen, LLC | ADD | 316,065 | 420,664 | +33.1% | $28.4M |
| CITADEL ADVISORS LLC | ADD | 233,450 | 394,373 | +68.9% | $26.6M |
| FIRST TRUST ADVISORS LP | NEW | — | 258,989 | — | $17.5M |
| MORGAN STANLEY | TRIM | 993,905 | 257,091 | -74.1% | $17.4M |
| FMR LLC | TRIM | 472,704 | 240,511 | -49.1% | $16.2M |
| HSBC HOLDINGS PLC | ADD | 125,717 | 216,949 | +72.6% | $14.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Orwin John A | Director | EXERCISE | 1,300 | — | — |
| Jun 15, 2026 | Orwin John A | Director | EXERCISE | 6,030 | — | — |
| Jun 15, 2026 | RENTON HOLLINGS | Director | EXERCISE | 6,030 | — | — |
| Jun 15, 2026 | Schmid John P. | Director | EXERCISE | 6,030 | — | — |
| May 11, 2026 | Hughes Owen | Director | AWARD | 11,250 | — | — |
| May 11, 2026 | Murphy Christopher M. | Chief Financial Officer | AWARD | 25,765 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | AWARD | 133,400 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | D | 133,400 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | AWARD | 305,500 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | D | 305,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ANAB.
Shares short
5,437,438
Settlement Sep 15, 2026
Change vs prior
+0.5%
Semi-monthly cycle
Days to cover
10.3
At avg daily volume
Of shares outstanding
≈18.4%
Estimate — not % of float
All ANAB filing & press-release reports (24)
- INST-CLUSTER reportAug 12, 2026
- 144 reportJul 3, 2026
- DEFA14A reportJul 3, 2026
- 144 reportJul 3, 2026
- 8-K reportJun 23, 2026
- 144 reportJun 17, 2026
- 144 reportJun 15, 2026
- 144 reportJun 11, 2026
- 144 reportJun 10, 2026
- 144 reportJun 8, 2026
- 144 reportJun 5, 2026
- 144 reportJun 5, 2026
- 144 reportJun 5, 2026
- 144 reportJun 3, 2026
- 144 reportJun 1, 2026
- 8-K reportMay 29, 2026
- 144 reportMay 28, 2026
- 144 reportMay 27, 2026
- 144 reportMay 15, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 24, 2026
- CLUSTER reportApr 2, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 3, 2026